Chemed

Chemed Corp. engages in the provision of healthcare and maintenance services. It operates through the VITAS and Roto-Rooter segments. The VITAS segment offers hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers. The Roto-Rooter segment includes plumbing, drain cleaning, water restoration, and other related services to residential and commercial customers. The company was founded in 1970 and is headquartered in Cincinnati, OH.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Chemed exceeds earnings expectations, focuses on strategic growth initiatives

Chemed's strong financial performance in 2022 was supported by targeted hiring and retention efforts.
Both VITAS and Roto-Rooter are focusing on improving staffing and revenue growth.
Chemed's strategic initiatives position the company well for future growth and operational efficiency.
The company's emphasis on culture and strategic approaches enhances valuation in the M&A market.

Chemed reports strong Q1 performance, optimistic about growth trajectory

Chemed's Q1 2023 earnings call highlighted a positive performance trajectory post-pandemic, with a focus on VITAS' growth and operational strategies. The company addressed challenges related to Medicare reimbursement rates and emphasized opportunities for further expansion and staff satisfaction.

Chemed's VITAS shines, Roto-Rooter adapts to consumer challenges

Chemed's Q2 2023 earnings call highlighted VITAS' strong performance and operational improvements post-pandemic.
Roto-Rooter faced challenges in consumer spending but focused on enhancing online presence and conversion rates.
Both segments showcased resilience amidst economic headwinds, with strategic initiatives in place to drive growth and operational efficiency.
Chemed's strategic cost management and revenue generation strategies position the company for sustainable growth and margin protection.

Chemed reports strong Q3 performance, eyes growth amid economic challenges

Chemed's diversified business segments showed resilience and growth potential, with VITAS Healthcare and Roto-Rooter both demonstrating strengths and addressing challenges. The company remains cautiously optimistic about 2024, focusing on operational efficiency and market dynamics for sustained performance.

Chemed's VITAS shines in Q4 with strong growth, Roto-Rooter faces challenges

Chemed's VITAS segment excelled with strong revenue growth and operational improvements, while Roto-Rooter faced challenges in call volume.
Management's confidence in sustained growth and margin improvement presents opportunities for both VITAS and Roto-Rooter in 2024.
Strategies to address challenges and capitalize on opportunities will be crucial for Chemed's divisions to meet their forecasted targets.
Overall, Chemed's performance in Q4 2023 sets a positive tone for the company's outlook and strategic initiatives moving forward.

Chemed excels in hospice segment, Roto-Rooter faces commercial challenges

Chemed's VITAS segment outperformed, while Roto-Rooter faced challenges, prompting strategic actions to enhance commercial performance and drive growth.

Chemed's VITAS shines in Q2 2024, Roto-Rooter faces revenue challenges

Chemed's VITAS segment is driving revenue growth and margin expansion, while Roto-Rooter faces challenges in revenue decline. The company aims to capitalize on growth opportunities in the hospice services sector.

Chemed's VITAS shines amid Roto-Rooter's challenges in Q3 2024

Chemed's earnings call showcased VITAS' resilience and growth prospects, while addressing Roto-Rooter's challenges and strategic adjustments. The company remains optimistic about adjusted net income outlook for the year.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Addus HomeCare

Pennant Group Inc

RadNet

Despite the macroeconomic challenges, rising dependence on telehealth and the dominance of AI are likely to drive the Zacks Medical - Outpatient and Home Healthcare industry. CHE, ADUS, RDNT and PNTG are well poised to gain from the prospects.

4 Promising Stocks From a Challenging Outpatient Home Health Industry

Chemed (CHE) records increases in drain cleaning, plumbing, excavation and water restoration revenues within the Roto-Rooter branch commercial business.

Chemed (CHE) Up on Roto-Rooter Sales Growth, Strong Admissions

PNTG vs. CHE: Which Stock Is the Better Value Option?

PNTG or CHE: Which Is the Better Value Stock Right Now?

CINCINNATI--(BUSINESS WIRE)--Chemed Corporation (NYSE:CHE) today announced that it will deliver a virtual presentation at the Oppenheimer 33rd Annual Healthcare Conference on Tuesday, March 14, 2023, at approximately 1:20 p.m. (ET). The virtual presentation will be webcast live and can be accessed, along with the presentation materials, through the Chemed website at www.chemed.com (Investor Relations).

Chemed Corporation to Present at the Oppenheimer 33rd Annual Healthcare Conference

Chemtrade Logistics Income Fund (OTC:CGIFF) Q4 2022 Earnings Conference Call February 23, 2023 10:00 AM ET Company Participants Rohit Bhardwaj - Chief Financial Officer Scott Rook - President & Chief Executive Officer Conference Call Participants Jacob Bout - CIBC Joel Jackson - BMO Capital Markets Steve Hansen - Raymond James Gary Ho - Desjardins Nelson Ng - RBC Capital Markets Operator Good morning, ladies and gentlemen, and welcome to the Chemtrade Logistics Income Fund Q4 2022 Annual Results Conference Call. At this time, all lines are in a listen-only mode.

Chemtrade Logistics Income Fund (CGIFF) Q4 2022 Earnings Call Transcript

Chemed Corporation (NYSE:CHE ) Q4 2022 Earnings Conference Call February 24, 2023 10:00 AM ET Company Participants Holley Schmidt – Assistant Controller Kevin McNamara – President and Chief Executive Officer Dave Williams – Executive Vice President and Chief Financial Officer Nick Westfall – President and Chief Executive Officer-VITAS Healthcare Corporation Subsidiary Conference Call Participants Joanna Gajuk – Bank of America Ben Hendrix – RBC Capital Markets Mike Wiederhorn – Oppenheimer Holley Schmidt Good morning. Our conference call this morning will review the financial results for the Fourth Quarter of 2022 ended December 31, 2022.

Chemed Corporation (CHE) Q4 2022 Earnings Call Transcript

Chemed (CHE) reports impressive sales growth in the Roto-Rooter subsidiary in the fourth quarter of 2022.

Chemed (CHE) Q4 Earnings Beat Estimates, Margins Contract

Chemed (CHE) delivered earnings and revenue surprises of 1.70% and 0.63%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Chemed (CHE) Tops Q4 Earnings and Revenue Estimates

CINCINNATI--(BUSINESS WIRE)--Chemed Corporation (Chemed) (NYSE: CHE), which operates VITAS Healthcare Corporation (VITAS), one of the nation's largest providers of end-of-life care, and Roto-Rooter, the nation's largest commercial and residential plumbing and drain cleaning services provider, reported financial results for its fourth quarter ended December 31, 2022, versus the comparable prior-year period, as follows: Consolidated operating results: Revenue increased 1.

Chemed Reports Fourth-Quarter 2022 Results

CINCINNATI--(BUSINESS WIRE)--Chemed Corporation (NYSE:CHE) announced today that the Board of Directors has declared a quarterly cash dividend of 38-cents per share on the Company's capital stock, payable on March 17, 2023, to shareholders of record as of February 27, 2023. This is equal to the dividend paid in December 2022. This represents the 207th consecutive quarterly dividend paid by Chemed in its 50 years as a public company.

Chemed Corporation Declares Quarterly Dividend of 38 Cents

CINCINNATI--(BUSINESS WIRE)--Chemed Corporation (NYSE: CHE) today announced that it will release financial results for the fourth quarter ended December 31, 2022, on Thursday, February 23, 2023, following the close of trading on the New York Stock Exchange. Chemed will host a conference call and webcast at 10 a.m., ET, on Friday, February 24, 2023, to discuss the company's quarterly results and to provide an update on its business.

Chemed To Report Fourth-Quarter 2022 Earnings February 23, Related Conference Call To Be Held On February 24

This stock has put up gains on par with those of Amazon and Apple over the past decade, but many investors have never heard of it.

This Low-Key Stock Jumped Nearly 600% Over the Last Decade

CINCINNATI--( BUSINESS WIRE )--Chemed Corporation (NYSE:CHE) today announced that it will present at the BofA Securities 2022 Virtual Home Care Conference on Tuesday, December 5, 2022, at 10:40 AM (ET).

Chemed Corporation to Present at the BofA Securities 2022 Virtual Home Care Conference

Upward revision of FY22 EPS guidance from strong Q3. Technicals supportive of strong buying action, accumulation, supporting the latest rally.

Chemed: Reaffirm Buy After Upsides To EPS Guidance, ROIC

Chemtrade Logistics Income Fund (OTC:CGIFF) Q3 2022 Earnings Conference Call November 8, 2022 10:00 AM ET Company Participants Rohit Bhardwaj - Chief Financial Officer Scott Rook - President & Chief Executive Officer Conference Call Participants Joel Jackson - BMO Capital Markets Steve Hansen - Raymond James Ben Isaacson - Scotiabank Nelson Ng - RBC Capital Markets Gary Ho - Desjardins Capital Markets Endri Leno - National Bank Operator Good morning, ladies and gentlemen and welcome to the Chemtrade Logistics Income Fund Q3 2022 Results Conference Call. [Operator Instructions] This call is being recorded on Tuesday, November 8, 2022.

Chemtrade Logistics Income Fund (CGIFF) Q3 2022 Earnings Call Transcript

Chemed's (CHE) full-year VITAS revenues, prior to Medicare Cap, are once again estimated to decline.

Chemed (CHE) Q3 Earnings Surpass Estimates, EPS View Up

Chemed Corporation (NYSE:CHE ) Q3 2022 Earnings Conference Call November 1, 2022 10:00 AM ET Company Participants Holley Schmidt - Assistant Controller Kevin McNamara - President and CEO Dave Williams - EVP and CFO Nick Westfall - President and CEO, Chemed VITAS Healthcare Corporation Subsidiary Conference Call Participants Joanna Gajuk - Bank of America Ben Hendrix - RBC Capital Markets Operator Good day, and thank you for standing by. Welcome to the Chemed Corporation's Third Quarter 2022 Earnings Conference Call.

Chemed Corporation (CHE) Q3 2022 Earnings Call Transcript

Chemed (CHE) delivered earnings and revenue surprises of 2.82% and 1.72%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Chemed (CHE) Q3 Earnings Surpass Estimates

CINCINNATI--(BUSINESS WIRE)--Chemed Corporation (Chemed) (NYSE: CHE), which operates VITAS Healthcare Corporation (VITAS), one of the nation's largest providers of end-of-life care, and Roto-Rooter, the nation's largest commercial and residential plumbing and drain cleaning services provider, reported financial results for its third quarter ended September 30, 2022, versus the comparable prior-year period, as follows: Consolidated operating results: Revenue declined 2.3% to $526 million GAAP Di

Chemed Reports Third-Quarter 2022 Results - Increases 2022 Earnings Guidance

CINCINNATI--(BUSINESS WIRE)--Chemed Corporation (NYSE:CHE) today announced that it will deliver a presentation at the 31st Annual Credit Suisse Healthcare Conference on Wednesday, November 9, 2022, at approximately 2:00 p.m.

Chemed Corporation to Present at the 2022 Credit Suisse Healthcare Conference

Chemed (CHE) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Why Chemed (CHE) is Poised to Beat Earnings Estimates Again

Chemed (CHE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Chemed (CHE) Q3 Earnings Expected to Decline

CINCINNATI--(BUSINESS WIRE)--Chemed Corporation (NYSE: CHE) today announced that it will release financial results for the third quarter ended September 30, 2022, on Monday, October 31, 2022, following the close of trading on the New York Stock Exchange.

Chemed To Report Third-Quarter 2022 Earnings October 31, Related Conference Call To Be Held On November 1

Investors need to pay close attention to Chemed (CHE) stock based on the movements in the options market lately.

News for Chemed Stock (CHE)